biostudies-literatureUnknown6(1)Heinhuis KM<h4>Importance</h4>Multiple immunostimulatory agonist antibodies have been clinically tested in solid tumors to evaluate the role of targeting glucocorticoid-induced tumor necrosis factor (TNF) receptor-related protein in anticancer treatments.<h4>Objective</h4>To evaluate the safety and activity of the fully human glucocorticoid-induced TNF receptor-related protein agonist IgG1 monoclonal antibody BMS-986156 with or without nivolumab in patients with advanced solid tumors.<h4>Design, setting, and participants</h4>This global, open-label, phase 1/2a study of BMS-986156 with or without nivolumab enrolled 292 patients 18 years or older with advanced solid tumors and an Eastern Cooperative Oncology Group performance status of 1 or less. Prior checkpoint inhibitor therapy was allowed. MonotherJAMA oncology100-107https://www.ebi.ac.uk/biostudies/studies/S-EPMC6865300biostudies-literatureSafety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial.PMC6865300Gazzah AHeinhuis KMPaz-Ares LBritschgi CRomano EJoerger MDi Nicola MMeniawy TLiu YPatah PDelord JPMoreno VCurigliano GWang RCarlino MRottey SSchilder RJO'Byrne KSiu LLBajaj GfalseSafety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial.<h4>Importance</h4>Multiple immunostimulatory agonist antibodies have been clinically tested in solid tumors to evaluate the role of targeting glucocorticoid-induced tumor necrosis factor (TNF) receptor-related protein in anticancer treatments.<h4>Objective</h4>To evaluate the safety and activity of the fully human glucocorticoid-induced TNF receptor-related protein agonist IgG1 monoclonal antibody BMS-986156 with or without nivolumab in patients with advanced solid tumors.<h4>Design, setting, and participants</h4>This global, open-label, phase 1/2a study of BMS-986156 with or without nivolumab enrolled 292 patients 18 years or older with advanced solid tumors and an Eastern Cooperative Oncology Group performance status of 1 or less. Prior checkpoint inhibitor therapy was allowed. Monother2020-01-01T00:00:00Z2020 Jan2026-04-12T23:52:11.266Z2021-02-19T10:38:35ZS-EPMC68653003169730810.1001/jamaoncol.2019.3848